Venture Capital: AI-Powered, Precision Medicine Startup Tempus Raises $275M In Equity And Debt

https://dailyalts.com/wp-content/uploads/2022/10/Tempus-Photo_Lab-1.jpg

Tempus raised additional equity funding at the same price per share as its previous fundraising round.

Tempus, which uses AI to advance healthcare solutions in drug discovery, clinical trials and diagnostics, has raised $275 million through equity from previous investors and debt financing from Ares Management.

The company has raised over $1.3 billion till date. It boasts of one of the world’s largest libraries of clinical and molecular data, and an operating system to make that data accessible and useful.

“In the last seven years, we’ve made great strides in developing and deploying smarter diagnostics not only in oncology, but neuropsychiatry, infectious disease, and cardiology,” said Eric Lefkofsky, Founder and CEO. “We are committed to achieving our mission in applying AI to healthcare broadly with a focus on deploying solutions at scale that have real impact on patient care today and research in the future.”

Earlier this week, GSK (NYSE: GSK) agreed to pay $70 million to access Tempus’ AI-enabled patient data platform with the aim of improving its clinical trial design, speeding up enrollment and identifying new drug targets.

“The collaboration leverages one of world’s largest sources of de-identified patient data to accelerate drug discovery, initially in oncology,” said GSK.

Tempus will use the new funds to scale its operations and capabilities, with a focus on building upon its disease agnostic platform designed to aggregate de-identified data and develop insights to power intelligent diagnostics.

Related Story: Atomwise To Collaborate With Sanofi On AI-Powered Drug Discovery

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Shape

Latest Alternative Investment News

https://dailyalts.com/wp-content/uploads/2022/12/defense-attorney-g17da42d37_640.jpg
Digital Assets: Mike Novogratz Hits Out At Sam Bankman-Fried, Calls For His Prosecution
December 2, 2022     Digital Assets, News

Mike Novogratz, the billionaire CEO of Galaxy Digital (TSE: GLXY), was unequivocally critical about Sam Bankman-Fried’s virtual New York Times (NYT) Dealbook Summit interview. “I’m hoping that the authorities get…

https://dailyalts.com/wp-content/uploads/2022/12/Home_Hero.png
FinTech: Monzo To Turn Profitable In 2023, Says CEO
December 2, 2022     FinTech, News

“We will be profitable in the next financial year,” TS Anil said at the summit on Thursday, though Monzo reported pre-tax losses of £119mn for the 12 months to the…

https://dailyalts.com/wp-content/uploads/2022/12/binary-geafeafdd2_640.jpg
Artificial Intelligence: OpenAI Launches ChatGPT, A New Conversational AI System
December 2, 2022     Artificial Intelligence, News

OpenAI has unveiled ChatGPT, a new AI system that interacts in a conversational way. As part of a dialogue format, ChatGPT answers followup questions, admits its mistakes, challenges incorrect premises,…

https://dailyalts.com/wp-content/uploads/2022/12/MKV-product-hero.jpg
Artificial Intelligence: Monarch’s Electric, Driver-Optional, Smart Tractor Now In Commercial Production

Monarch Tractor has rolled out the first production model of the MK-V tractor that combines electrification, automation, and data analysis to help farmers reduce their carbon footprint, improve field safety,…